<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015829</url>
  </required_header>
  <id_info>
    <org_study_id>S-20190058</org_study_id>
    <secondary_id>19/34844</secondary_id>
    <nct_id>NCT05015829</nct_id>
  </id_info>
  <brief_title>Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis</brief_title>
  <acronym>DALLAS</acronym>
  <official_title>Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When aortic valve-area is &lt;1.0cm2 and transvalvular mean-gradient is &gt;40mmHg, the diagnosis&#xD;
      of severe aortic stenosis (AS) is straightforward. However, some patients present with an&#xD;
      apparently reduced valve-area, despite transvalvular-gradient &lt;40mmHg; Low-flow, low-gradient&#xD;
      aortic stenosis (LFLG AS). When a patient with LFLG AS also presents with LVEF &lt;50%,&#xD;
      guidelines recommends performing a Low-Dose Dobutamine-echocardiography (LDDE) to confirm&#xD;
      true-severe AS. However, nearly 30% of patients with LFLG AS do not show an adequate respond&#xD;
      to Dobutamine. More commonly, patients present with the combination of LFLG AS, despite&#xD;
      LVEF≥50%. In this group of patients the use of LDDE remains undisclosed.&#xD;
&#xD;
      The purpose of this study is to examine the safety and diagnostic usefulness of LDDE in&#xD;
      patients with LFLG AS with LVEF≥50%. Furthermore we will examine factors associated with&#xD;
      inadequate response to LDDE.&#xD;
&#xD;
      150 symptomatic and/or asymptomatic patients with LFLG and LVEF≥50% and a control group with&#xD;
      LVEF&lt;50% will be enrolled at the Department of Cardiology, OUH. Patients will undergo&#xD;
      clinical evaluation including LDDE, blood analyses, CT-scan and cardiac Mri.&#xD;
&#xD;
      Only a limited number of studies examine the possible use of LDDE in patients with LFLG AS&#xD;
      and LVEF≥50% and no study has been performed documenting the safety and feasibility.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects during Dobutamine infusion</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>The occurrence of angina pectoris, severely high systolic blood pressure &gt;200 mmHg or ventricular premature beats Lown Grade &gt;3 or supra-ventricular arrhythmias or tachycardia assessed by ECG.&#xD;
Occurrence of signs of echocardiographic subvalvular obstruction; (systolic anterior motion of the mitral leaflet (SAM), high velocities (&gt;2 m/sec) in the LV outflow tract and late peaking systolic jet).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>a) Gender (male/female).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>b) Aortic valve calcification assessed by cardiac CT (AU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>c) Myocardial fibrosis assessed by MRi (%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>d) Baseline myocardial systolic and diastolic function estimated by echocardiography (Global Longitudinal Strain (%), Strain Ratesystolic (SRs), deceleration time of mitral E-wave (ms) and end-systolic wall-stress corrected LVEF (dynes).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>e) The ongoing use of beta-blockers (%, dosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with flow-reserve</measure>
    <time_frame>Dobutamine infusion, up to 30 minutes</time_frame>
    <description>f) Association with outcomes (rate of AVR, hospitalization for cardiac failure, death).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ability of LDDE to predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis.</measure>
    <time_frame>1 day til 3 years</time_frame>
    <description>Rate of AVR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ability of LDDE to predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis.</measure>
    <time_frame>1 day til 3 years</time_frame>
    <description>Hospitalization for cardiac failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ability of LDDE to predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis.</measure>
    <time_frame>1 day til 3 years</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The ability of LDDE to predict outcome in patients with paradoxical low-flow, low-gradient aortic stenosis.</measure>
    <time_frame>1 day til 3 years</time_frame>
    <description>Cardiovascular mortality</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Valvular Stenosis</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Classical low-flow low-gradient aortic stenosis</arm_group_label>
    <description>LVEF&lt;50% SVi &lt; 35.0 mL/m2 Aortic mean gradient &lt; 40 mmHg AVA &lt; 1.0 cm2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradoxical low-flow low-gradient aortic stenosis</arm_group_label>
    <description>LVEF&gt;50% SVi &lt; 35.0 mL/m2 Aortic mean gradient &lt; 40 mmHg AVA &lt; 1.0 cm2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dobutamine Stress Echocardiography</intervention_name>
    <description>Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.</description>
    <arm_group_label>Classical low-flow low-gradient aortic stenosis</arm_group_label>
    <arm_group_label>Paradoxical low-flow low-gradient aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with LFLG AS followed at the Department of Cardiology, Odense University Hospital&#xD;
        will be offered participation in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Low-flow (SVi&lt;35 ml/m2) low-gradient (mean gradient &lt;40 mmHg) AS with estimated&#xD;
             AVA&lt;1.0 cm2 referred to the Department of Cardiology, Odense University Hospital.&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other moderate-severe valvular heart disease.&#xD;
&#xD;
          2. Unwilling to participate in the study.&#xD;
&#xD;
          3. Poor echocardiographic window.&#xD;
&#xD;
          4. Inability to follow-up due to temporary citizenship Registration Number (CPR-Number)&#xD;
             or emigration within the study period.&#xD;
&#xD;
          5. Pregnant women.&#xD;
&#xD;
          6. Patients with severe chronic renal failure (eGFR&lt;40 ml/min) will not undergo cardiac&#xD;
             MRi or CT angiography.&#xD;
&#xD;
          7. Known contrast allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nils Mogensen, MD</last_name>
    <phone>61286371</phone>
    <phone_ext>+45</phone_ext>
    <email>nils.sofus.borg.mogensen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fune</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Mogensen, MD</last_name>
      <phone>61283671</phone>
      <phone_ext>+45</phone_ext>
      <email>nils.sofus.borg.mogensen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Nils Sofus Borg Mogensen</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

